Spyre Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
SYRE$103.86+7.5%Stored close · as of Nov 6, 2026
Contents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: November 4, 2025
| Spyre Therapeutics, Inc. | |
| By: | /s/ Scott Burrows |
| Scott Burrows | |
| Chief Financial Officer | |
| (Principal Financial Officer and Principal Accounting Officer) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.